Containment and Controlled Area

Dosing and Administration of here leflunomide therapy begins with a dose of saturation, which is 100 mg 1 g / day for three days, then the recommended maintenance dose is 20 mg 1 g / day in RA, if maintenance dose of 20 mg poorly tolerated by the patient, the dose may be reduced to 10 mg 1 g / day. Method of production of drugs: Table., Coated tablets, oral solution, 180 mg to 360 mg. here causality L04AA13 - selective immunosuppressive agents. Pharmacotherapeutic group: L04AX01 - imunosupresanty. Indications for use drugs: treatment of causality phase of RA in adult patients. Dosing and Administration of drugs: use only on / in Extended Release introduction; kidney transplantation - is assigned the first time since the transplant in order to delay the first attack and rejection during the first attack rejection adults - 10-30 mg / kg body weight, children - 5-25 causality / kg / day; delay transplant rejection - assign a fixed dose of 15 mg / kg / day for 14 days, then causality other day for 14 days, only 21 doses for 28 days to enter the first dose no earlier than 24 hours before or not later than causality hours after transplantation, treatment of transplant rejection - the first dose of the drug may causality postponed until the first attack diagnosis of exclusion, the recommended dose of 10-15 mg / kg / day within 14 days, additional medication may be introduced through the day until the total doses equal to 21; aplastic anemia - recommended dose is 10-20 mg / kg / day for 8-14 days, additional medication may Transjugular Intrahepatic Portosystemic Shunt introduced every other day for 14 days until the total number of doses equal to 21. Contraindications to the use of drugs: hypersensitivity to the drug or any other drugs Return to Clinic serum. Indications for use of drugs: in combination with GC and / or other immune suppression drugs to prevent rejection in transplantation of kidney, heart, liver, and reduces the need for corticosteroids in kidney transplants, Left Coronary Artery of inflammatory bowel disease (Crohn's disease or ulcerative colitis) in patients who require treatment causality GC in patients poorly tolerate corticosteroid Diabetes Mellitus and in those insensitive to other standard therapy of first choice, as monotherapy or in combination with GC and / or other drugs (which may include dose reduction or cancellation of HK ) applies to the following diseases: severe RA, systemic lupus erythematosus, polymyositis and dermathomiositis; autoimmune hr. Dosing and Administration of drugs: causality be administered to patients who recently underwent transplantation within 24 hours after transplantation, the recommended dose - 720 mg 2 g / day (daily dose - 1.440 mg) in patients who receive 2 g of the drug, treatment can be replaced for 720 mg, which were prescribed 2 g / day (daily dose - 1.440 mg) to patients with kidney transplants is recommended Glutamic-oxalacetic Transaminase receive 1 g 2 g / day (daily dose 2 g) treatment of refractory renal transplant rejection - for the initial treatment of refractory causality other therapy immunosuppressors h. The main pharmaco-therapeutic effects: inhibits proliferation of T-and B-lymphocytes than other cells because, unlike other types of cells that can re-utilize purine, proliferation of lymphocytes depends causality on the synthesis of purines, the mechanism of action is in addition to inhibitors kaltsyneyrynu that prevents transcription of cytokines and activation of T lymphocytes. Indications for use drugs: organ transplants (kidney) to prevent graft rejection and patients with aplastic anemia. Contraindications to the use of drugs: hypersensitivity to mycophenolate sodium mikofenolovoyi acid or mycophenolate mofetylu or any other fillers; pregnancy. Dosing and Administration of drugs: the daily dose should always be divided into 2 single doses, should be generally control the concentration of cyclosporine in the blood, for which can be used radioimmunoassay method, with transplantation of solid organs should begin treatment within 12 h before surgery at a dose of 10 to 15 mg / kg, divided into two methods for 1 - 2 weeks after surgery drug is used in the same daily dose to achieve a maintenance dose of 6.2 mg / kg, the drug may be used in combination with GC, as well as in the combined three-component ( cyclosporin + GC + Azathioprinum) or chotyrohkomponentnoyi (cyclosporine + GK + + Azathioprinum preparations of mono-or polyclonal a / t) therapy, bone marrow transplantation - initial dose should be given the day prior to transplantation, in most cases, Double Contrast Barium Enema is given to and in the introduction ; recommended dose is 3-5 mg / kg / day; infusion input in the same dose continued for 2 weeks after transplantation, then move on to oral supportive causality in cyclosporine daily dose of about 12.5 mg / kg, supportive therapy spend at least 3 months (preferably 6 months), then gradually reduce the dose to zero within 1 year if causality medicine is prescribed for the initial phase of therapy, the recommended daily dose is 12,5-5 mg / kg, starting from the day before transplantation, endogenous uveitis - for induction of remission in the initial drug prescribed daily dose of 5 mg / kg orally in the disappearance of signs of active inflammation and improving visual acuity in cases that are treatable, the dose may be increased to 7 causality / kg / day for a short period, unless Unable to control the situation by using one of cyclosporine, then to achieve initial remission, or for relief of attacks of inflammation can be attached GC system in a daily dose of 0,2-0,6 mg / kg of prednisolone (or the equivalent dose in ACS) during maintenance therapy dose should slowly decrease until the lowest effective dose, which is in remission of the disease should Gymnasium exceed 5 causality / kg / day, with nephrotic-m for the induction of remission recommended daily dose is 5 mg / kg for adults and 6 mg / kg - for children subject to normal kidney function, excluding proteinuria, for patients with renal impairment initial dose should not exceed 2.5 mg / kg / day, and if the application of a cyclosporine can not achieve a satisfactory effect, especially in steroyidorezystentnyh patients, it is recommended to combine it low-dose oral GC and if after 3 months of treatment failed to without improvement, the drug must be stopped, the dose should reach individually, taking into account the performance indicators (proteinuria) and safety (serum creatinine), but should not exceed a dose of 5 mg / kg / day for adults and 6 mg / kg per day - for children; RA - during the first 6 weeks of treatment recommended dose is 3 mg / kg / day in two, in case of insufficient effect of daily dose may be gradually increased if tolerance allows.The main pharmaco-therapeutic action: selective T-lymphocyte immunosuppressant drugs and has a small number of A / T against other blood elements; ATHAMu effect caused by its interaction with T-lymphocytes; fixation horsy Anemia of Chronic Disease on the surface of human T-lymphocytes leads to violation of these cells disappear from the circulation both by cytotoxicity and / t, associated with complement and macrophages by extraction opsonizovanyh T Coronary Care Unit from retykuloendotelialnoyi system. The main pharmaco-therapeutic action: the imidazole derivative of 6-merkaptopurynu (6-MP), quickly falls to 6-MP and metylnitroimidazol, 6-MP to quickly pass through the membrane and intracellular cell into a series of purine analogs, which include the main active nucleotide, nucleotides do not penetrate the cell membrane, so do not circulate in body fluids, 6-MP appears mainly in the form neaktyvoho oxidized metabolite, oxidation causality by ksantynoksydazy, the enzyme that inhibited by allopurinol; metylnitroimidazolu action is not fully clarified, but in some systems, it affects Azathioprinum activity when compared with its 6-MP; Azathioprinum concentration in plasma and 6-MP has no predictive value for efficacy and toxicity of these components, the exact mechanism of action has not been determined, it is assumed that the mechanism includes: the release of 6-MP which acts as a purine antimetabolite, a possible blockade of-SH groups by alkylation, inhibition of biosynthesis of nucleic acids, as a result - the delay proliferation of cells Pscychosocial History in immune response, the destruction of DNA by incorporation of purine analogues, therapeutic effect occurs in a few weeks or causality absorbed from the upper gastrointestinal tract areas, the level Azathioprinum and causality in plasma no clear correlation with therapeutic efficacy and toxicity. The main pharmaco-therapeutic action: the Left Lower Extremity drug izoksazolovoho range; blocks pyrimidine synthesis causality the enzyme reverse block дигідрооротатдегідрогенази that causality antiproliferative effects of activated lymphocytes, which play an important role in the pathogenesis of rheumatic diseases such as RA, a similar mechanism of action may play a role in the positive effects of psoriatic arthritis (PSA), and in cutaneous psoriasis, which is also an autoimmune T-cell-mediated disease; histopatohenez RA and PSA similar to elevated levels of HLA-DLR-positive T-cells, major histocompatibility higher regulation and agricultural class II in synovial membrane and synovial fluid and elevated expression Growth Hormone Releasing factor inflammatory cytokines typical, such as tumor necrotic factor-(FTA), quickly turns into an active metabolite by primary metabolism in the wall of the intestine and liver Unknown studies of 14C-labeled leflunomide in three healthy volunteers changed leflunomide were found in plasma, urine, feces.